Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 28, 2025
Distillery Therapeutics

Guanine synthesis inhibitor for glioblastoma

BioCentury | May 29, 2024
Discovery & Translation

Science Spotlight: Cimeio’s cell-shielding technology, stopping EBV-driven cancer and more

BioCentury’s roundup of translational innovations
BioCentury | Mar 26, 2024
Distillery Therapeutics

Inhibiting SLC25A51 for AML

BioCentury | Oct 13, 2023
Discovery & Translation

eGenesis’ kidney xenotransplant; plus Epirium, Neurimmune and more

BioCentury’s roundup of translational innovations
BioCentury | Sep 12, 2023
Discovery & Translation

Lurie winners show mitochondria is more than a powerhouse

Northwestern’s Navdeep Chandel and Harvard’s Vamsi Mootha share the FNIH’s 2023 prize for pioneering mitochondrial biology beyond ATP
BioCentury | Nov 30, 2022
Deals

Nov. 29 Quick Takes: Horizon names three possible buyers, discloses early M&A talks

Plus: TCG, Lux lead $96M A round for Cajal and updates from Sana, X4, Roche, Ribon and more
BioCentury | Nov 5, 2022
Discovery & Translation

A gene therapy to drive hyperexcitable neurons back to baseline; plus a conditionally active IL-2 and more

BioCentury’s roundup of translational news
BioCentury | Sep 16, 2022
Discovery & Translation

A selective JAK-1 inhibitor; plus deep learning methods to explore new protein designs and more

BioCentury’s roundup of translational news
BioCentury | Mar 24, 2022
Discovery & Translation

IDO thwarts antitumor T cell responses; plus Lumen, Loki, Genentech and more

BioCentury’s roundup of translational news
BioCentury | Feb 18, 2022
Management Tracks

Nelson, Collins to fill void left by Lander at White House

Plus Clayton joins Horizon as EVP, general counsel and updates from Ribon, Leo and more
Items per page:
1 - 10 of 104